蓝晓科技(300487)：高毛利业务占比提升 生科板块加码投入

Group 1 - The company reported a revenue of 1.247 billion yuan in the first half of 2025, a year-on-year decrease of 3.64%, while the net profit attributable to shareholders increased by 10.01% to 445 million yuan [1][2] - In Q2 2025, the company achieved a revenue of 671 million yuan, a year-on-year increase of 1.06% and a quarter-on-quarter increase of 16.27%, with a net profit of 251 million yuan, reflecting a year-on-year growth of 7.00% and a quarter-on-quarter growth of 30.16% [1][2] - The gross profit margin for the first half of 2025 was 51.26%, an increase of 3.8 percentage points year-on-year, indicating improved profitability [2] Group 2 - The company is increasing its investment in the life sciences sector, with a planned high-standard new industrial park in Pucheng, with a total investment of 1.15 billion yuan [3] - The life sciences segment generated revenue of 320 million yuan in the first half of 2025, a year-on-year increase of 12.43%, driven by strong growth in polypeptide solid-phase synthesis carrier business [3] Group 3 - The water treatment segment is seeing an increase in market share, with high-end drinking water contracts established with major clients, leading to continued market penetration [4] - The company achieved revenue of 359 million yuan in the water treatment and ultra-purification segment, a year-on-year increase of 11.25% [4] - The lithium extraction project in Tibet is progressing, with the first production line of the Chaka project successfully trialing, aiming to become a benchmark for "green zero-carbon direct lithium extraction" [4] Group 4 - The company has adjusted its revenue forecasts for 2025-2027, expecting revenues of 3.032 billion, 3.767 billion, and 4.748 billion yuan, with net profits of 987 million, 1.239 billion, and 1.649 billion yuan respectively [5] - The company maintains a "buy" rating based on its R&D advantages and long-term growth potential [5]